Literature DB >> 26295570

Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.

Abstract

Entities: Chemical

Year: 2015 PMID： 26295570 PMCID： PMC4546425 DOI： 10.1371/journal.pone.0136515

Source DB: PubMed Journal: PLoS One ISSN： 1932-6203 Impact factor: 3.240

× No keyword cloud information.

Notice of Republication

This article was republished on August 7, 2015, to replace Fig 2, which was incorrect. The publisher apologizes for the error. Please download this article again to view the correct version.

1 in total

1. Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.

Authors: Alberto Ferreira; Alexandros Sagkriotis; Melvin Olson; Jingsong Lu; Charles Makin; Fran Milnes
Journal: PLoS One Date: 2015-07-24 Impact factor: 3.240

1 in total